Table 2 Baseline characteristics of the β-blocker and Non-β-blocker therapy groups
From: Association between β-blocker use and mortality in critically ill patients: a nested cohort study
| Variable |
β-blocker N = 89 |
Non-β-blocker N = 434 | P value | PS* Adjusted P Value |
|---|---|---|---|---|
| Age (years) mean ± SD | 65.6 ± 14.78 | 49.7 ± 21.88 | < 0.0001 | 0.37 |
| Gender, n (%) | ||||
| Female | 35 (39.3) | 97 (22.4) | 0.0008 | 0.09 |
| Male | 54 (60.7) | 337 (77.7) | ||
| Diabetes, n (%) | 61 (68.5) | 147 (33.9) | < 0.0001 | 0.31 |
| Admission category, n (%) | ||||
| Non-operative | 78 (87.6) | 357 (82.3) | 0.21 | 0.93 |
| Post-operative | 11 (12.4) | 77 (17.7) | ||
| APACHE II score, mean ± SD | 24.9 ± 8.01 | 22.4 ± 8.09 | 0.008 | 0.48 |
| SOFA score Day 1, mean ± SD | 8.7 ± 3.65 | 8.8 ± 3.47 | 0.97 | 0.22 |
| Sepsis, n (%) | 18 (20.2) | 104 (24.0) | 0.44 | 0.03 |
| Septic Shock, n (%) | 23 (25.84) | 102 (23.5) | 0.64 | 0.08 |
| Chronic Respiratory disease, n (%) | 10 (11.2) | 60 (13.8) | 0.51 | 0.05 |
| Chronic Cardiac disease n (%) | 24 (27.0) | 53 (12.2) | 0.0003 | 0.16 |
| Chronic liver disease n (%) | 10 (11.2) | 26 (6.0) | 0.07 | 0.05 |
| Chronic immunosuppression, n (%) | 9 (10.1) | 38 (8.8) | 0.68 | 0.89 |
| Chronic renal disease, n (%) | 14 (15.7) | 41 (9.5) | 0.07 | 0.60 |
| Creatinine (micromol/L), mean ± SD | 194.0 ± 152.89 | 148.8 ± 143.10 | 0.01 | 0.52 |
| Estimated GFR, mean ± SD | 77.3 ± 62.8 | 54.5 ± 52.8 | 0.001 | 0.57 |
| Vasopressor, n (%) | 55 (61.8) | 286 (65.9) | 0.45 | 0.64 |
| Statin use, n (%) | 34 (38.2) | 34 (7.8) | < 0 .0001 | 0.89 |